194982-27-9

Upstream product

• 194981-58-3 3-phenyl-7-propylbenzo[d]isoxazol-6-ol 
• 101110-28-5 2,4-dihydroxy-3-allylbenzophenone 
• 2549-87-3 2-hydroxy-4-prop-2-enyloxybenzophenone 
• 109-64-8 1,3-dibromo-propane 
• 194981-56-1 (2,4-dihydroxy-3-propyl-phenyl)-phenyl-methanone oxime 
• 79557-81-6 (2,4-dihydroxy-3-propylphenyl)phenylmethanone 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Amphipathic 3-phenyl-7-propylbenzisoxazoles; human PPaR γ, δ and α agonists

A series of amphipathic 3-phenylbenzisoxazoles were found to be potent agonists of human PPARα, γ and δ. The optimization of acid proximal structure for in vitro and in vivo potency is described. Results of po dosed efficacy studies in the db/db mouse mod

Benzisoxazole-derived antidiabetic compounds

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.